# A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

> **NCT03019809** · PHASE2 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 30 (estimated)

## Conditions studied

- Wiskott-Aldrich Syndrome
- Hematopoietic Stem Cell Transplantation
- Graft Failure

## Interventions

- **BIOLOGICAL:** G-CSF for Conditioning before HSCT.
- **BIOLOGICAL:** Plerixafor for Conditioning before HSCT.

## Key facts

- **NCT ID:** NCT03019809
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-12
- **Final completion:** 2019-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019809, "A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03019809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*